Rocket Pharmaceuticals Q2 EPS $(0.82) Misses $(0.79) Estimate; Cash, Cash Equivalents And Investments Of Approximately $307M; Expected Operational Runway Into 1H 2025
Portfolio Pulse from Benzinga Newsdesk
Rocket Pharmaceuticals reported Q2 losses of $(0.82) per share, missing the analyst consensus estimate of $(0.79) by 3.8 percent. This is a 1.2 percent increase over losses from the same period last year. The company has cash, cash equivalents and investments of approximately $307M, providing an expected operational runway into 1H 2025.
August 10, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rocket Pharmaceuticals' Q2 earnings per share missed estimates, which could negatively impact investor sentiment. However, the company's substantial cash and investments provide a solid financial footing until 1H 2025.
The company's missed earnings per share estimate could lead to a short-term negative reaction in the stock market. However, the company's strong cash position could mitigate some of this negative impact by demonstrating financial stability.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100